ArticleMolecular medicine (Cambridge, Mass.)2018
Targeting DEC-205
Article in Molecular medicine (Cambridge, Mass.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Tunable wrinkled topographies direct dendritic cell maturation and immune phenotypes.Acta biomaterialia · 2026Article
- Reprogramming autoimmunity: inducing antigen-specific tolerance via apoptotic mimicry in an experimental model of multiple sclerosis.Journal of neuroinflammation · 2025Article
- Functional Specialization and Collaboration of cDC2 Subsets in CD4+ T Cell Priming and Differentiation.Immunological reviews · 2025Review
- Multiple sclerosis: molecular pathogenesis and therapeutic intervention.Signal transduction and targeted therapy · 2025Review
- Tolerogenic antigen-specific vaccine induces VISTA-enriched regulatory T cells and protects against arthritis in DRB1∗04:01 mice.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- Exploring Clec9a in dendritic cell-based tumor immunotherapy for molecular insights and therapeutic potentials.NPJ vaccines · 2025Review
- Physicochemical properties, biological activities, applications, and protective potential of the skeletal system ofFrontiers in pharmacology · 2025Review
- Emerging T cell immunoregulatory mechanisms in multiple sclerosis and Alzheimer's disease.Frontiers in aging neuroscience · 2024Review
- The Application of Nanovaccines in Autoimmune Diseases.International journal of nanomedicine · 2024Review
- Epitope-based precision immunotherapy of Type 1 diabetes.Human vaccines & immunotherapeutics · 2023Article
- Dendritic cell marker Clec4a4 deficiency limits atherosclerosis progression.Atherosclerosis plus · 2023Article
- Life and death of tolerogenic dendritic cells.Trends in immunology · 2023Review
- Tolerogenic dendritic cells in type 1 diabetes: no longer a concept.Frontiers in immunology · 2023Review
- Cell-targeted vaccines: implications for adaptive immunity.Frontiers in immunology · 2023Review
- Targeted delivery of autoantigen to dendritic cells prevents development of spontaneous uveitis.Frontiers in immunology · 2023Article
- Impact of disease-modifying therapy on dendritic cells and exploring their immunotherapeutic potential in multiple sclerosis.Journal of neuroinflammation · 2022Review
- Rebooting Regulatory T Cell and Dendritic Cell Function in Immune-Mediated Inflammatory Diseases: Biomarker and Therapy Discovery under a Multi-Omics Lens.Biomedicines · 2022Review
- Crosstalk between dendritic cells and regulatory T cells: Protective effect and therapeutic potential in multiple sclerosis.Frontiers in immunology · 2022Review
- Myelin Peptide-Mannan Conjugate Multiple Sclerosis Vaccines: Conjugation Efficacy and Stability of Vaccine Ingredient.Vaccines · 2021Article
- Tolerogenic Dendritic Cell-Based Approaches in Autoimmunity.International journal of molecular sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDendritic cells (DC) induce adaptive responses against foreign antigens, and play an essential role in maintaining peripheral tolerance to self-antigens. Therefore they are involved in preventing fatal autoimmunity. Selective delivery of antigens to immature DC via the endocytic DEC-205 receptor on their surface promotes antigen-specific T cell tolerance, both by recessive and dominant mechanisms. We provide evidence that the induction of antigen-specific T cell tolerance is not a unique property of CD11c
methodsWe employed a fusion between αDCIR2 antibodies and the highly encephalitogenic peptide 139-151 of myelin-derived proteolipid protein (PLP
resultsConsistent with previous studies targeting other cell surface receptors, EAE protection mediated by αDCIR2-PLP
conclusionsThese results suggest that multiple mechanisms can lead to the expansion of the Treg population, depending on the DC subset and receptor targeted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.